Table 1 Baseline characteristics of the trial participants
Variable | Total (n = 10) |
|---|---|
Age at inclusion, y, median (IQR) | 18.7 (17.9–20.2) |
Male sex, n (%) | 4 (40) |
Age at diagnosis, m, median (IQR) | 6.9 (0.1–11.4) |
Mutation of ATP1A3 | |
p.D801N | 5 (50) |
Other mutations | 5 (50) |
Total paroxysmal events per week | |
Median (IQR) | 3.88 (3.19–4.85) |
Mean (SD) | 4.39 (1.95) |
Chronic medications, n (%) | 9 (90) |
Number, median (IQR) | 3 (3–4) |
Flunarizine, n (%) | 8 (80) |
Acetazolamide, n (%) | 2 (20) |
Permanent neurologic deficiency | |
Pyramidal syndrome | 8 (80) |
Cerebellar syndrome | 8 (80) |
Dystonia | 8 (80) |
Cognitive/ behavioral dysfunction | 6 (60) |